Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prolac-T
- Development stage
- Preclinical
- Lead developer
- Cell Biotech International
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
Prolac-T is a postbiotic product developed by Cell Biotech International, comprising heat-killed (thermally inactivated) Lactobacillus acidophilus CBT-LA1 cells and their metabolites. It functions as a non-viable bacterial preparation that combines parabiotic effects from the cell structures with postbiotic effects from the metabolites. Prolac-T exhibits bactericidal and bacteriostatic properties against various diarrheal pathogens and has the capacity to directly remove Gram-negative bacteria and neutralize their toxic lipopolysaccharides (LPS), which are known triggers for inflammation and oxidative stress. Additionally, research indicates potential hypocholesterolemic effects. It is primarily utilized as an ingredient in gut health dietary supplements and probiotic formulations, often in combination with live probiotics protected by patented coating technologies.
- Brand names
- Prolac-T
- Other names
- Prolac-T postbioticheat-killed Lactobacillus acidophilus CBT-LA1
Beyond the preview
Go deeper on Prolac-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prolac-T.